Concepedia

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Matteo Santoni, Sebastiano Buti, Zin Myint, Marco Maruzzo, Roberto Iacovelli, Martin Pichler, Jindřich Kopecký, Jakub Kucharz, Mimma Rizzo, Luca Galli,

European Urology Oncology · 2023 · 77 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Marco Gerlinger, Andrew J. Rowan, Stuart Horswell et al. · New England Journal of Medicine · 2012 · 7.8K citations · Full text

, , +14

Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Claudia Allemani, Tomohiro Matsuda, V Di Carlo et al. · The Lancet · 2018 · 6.2K citations · Full text

, , +17

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.6K citations · Full text

, , +11

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text

, , +9

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

, , +6